Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Using laboratory-grown roundworms as well as human and mouse eye tissue, researchers have identified a new potential mechanism for age-related macular degeneration—the leading cause of blindness among older adults.
Scientists at the University of Pennsylvania School of Veterinary Medicine report findings of a gene therapy to treat a severe form of Leber congenital amaurosis, caused by mutations in the NPHP5 gene.
NEI-funded research at the University of Rochester has led to the development of a 3D lab model that mimics the part of the human retina affected in age-related macular degeneration.
While it isn’t surprising that infants and children love to look at people’s movements and faces, recent research from Rochester Institute of Technology studies exactly where they look when they see someone using sign language.
NEI-funded research at Scripps Research Institute has turned up more than a dozen gene variants linked to MacTel, a rare eye disease. The variants are likely causing the condition to develop and worsen for a significant share of patients.
Training neural networks to perform tasks, such as recognizing images or navigating self-driving cars, could one day require less computing power and hardware thanks to a new artificial neuron device.
In a massive screen of 400 mouse genes, Yale School of Medicine researchers have identified 40 genes actively involved in suppression of axon regeneration in central nervous system cells.
The latest research from the John A. Moran Eye Center reveals how an oxidized form of cholesterol can change choroidal endothelial cells into cells that become scars and may wreak havoc in the eyes of age-related macular degeneration (AMD) patients.
Researchers for the first time analyzed genes in more than 34,000 people with glaucoma across multiple ancestries and found 44 new genetic variants that may lead to new treatment targets.